Comparison of dose selection based on target engagement versus inhibition of receptor-ligand interaction for checkpoint inhibitors
Abstract Immune checkpoint inhibitors block the interaction between a receptor on one cell and its ligand on another cell, thus preventing the transduction of an immunosuppressive signal. While inhibition of the receptor-ligand interaction is key to the pharmacological activity of these drugs, it ca...
Saved in:
Main Authors: | Sarah A. Head (Author), Carter Johnson (Author), Saheli Sarkar (Author), Andrew Matteson (Author), Diana H. Marcantonio (Author), Fei Hua (Author), John M. Burke (Author), Joshua F. Apgar (Author), David Flowers (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions
by: Diana H. Marcantonio, et al.
Published: (2022) -
Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
by: Joshuaine Grant, et al.
Published: (2023) -
Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
by: Ali N. Kamali, et al.
Published: (2023) -
First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population
by: Feiyang Zhang, et al.
Published: (2024) -
A systems pharmacology model for gene therapy in sickle cell disease
by: Bo Zheng, et al.
Published: (2021)